Article info

Original research
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Authors

  1. Correspondence to Dr David G Warnock, The University of Alabama at Birmingham, Birmingham, AL 35205, USA; dwarnock{at}uab.edu
View Full Text

Citation

Wallace EL, Goker-Alpan O, Wilcox WR, et al
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Publication history

  • Received June 2, 2023
  • Accepted September 10, 2023
  • First published November 8, 2023.

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.